Oncology
1 drug is in development for Testicular Cancer.
- Companies
- 1
- Clinical trials
- 8
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Testicular Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| CTIM-76 | Context Therapeutics Inc. (CNTX) |
About this indication
Testicular Cancer context
Oncology·MeSH: Testicular Neoplasms (D013736)
Prevalence
9.7 / 100K
Incidence
1.3 / 100K/yr
Frequently asked questions
How many drugs are in development for Testicular Cancer?
BioSniper tracks 1 drug in development for Testicular Cancer across 1 company.
How many clinical trials target Testicular Cancer?
There are 8 clinical trials targeting Testicular Cancer tracked by BioSniper.
What is the prevalence of Testicular Cancer?
The estimated prevalence of Testicular Cancer is approximately 9.7 per 100,000 population.